Sol-Gel Completes Last Patient Visit in Pivotal Phase 3 SGT-610 Trial
SLGL has more than doubled off its 52-week low of $23.15.
Summary
Sol-Gel announced last patient last visit in its pivotal Phase 3 trial of SGT-610 for Gorlin syndrome, with top-line results still expected in late November 2026.
Key Events · Product Development and Regulatory · SLGL
-
Last Patient Last Visit Achieved
The final patient completed the last scheduled study visit in the Phase 3 SGT-610 trial for Gorlin syndrome, marking completion of the treatment and follow-up phase.
-
Trial Enrollment and Completion
113 patients were enrolled, of whom 102 completed the 12-month randomized, double-blind, vehicle-controlled study.
-
Top-Line Data Timing Confirmed
Top-line results remain on track for late November 2026, following database lock and statistical analysis.
-
Primary Endpoint
The primary endpoint is the number of new basal cell carcinomas on the face at month 12 after twice-daily treatment.
Analysis · SLGL · Life Sciences
The last patient has completed the final scheduled visit in the Phase 3 trial of SGT-610 for Gorlin syndrome, moving the program into database lock and statistical analysis. Top-line results remain on track for late November 2026. This is a key operational milestone that de-risks the trial timeline and sets up the binary data readout that will determine the company's lead asset.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 31.5% of the 1750 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLGL was trading at $63.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $207.7M. The 52-week trading range was $23.15 to $97.97. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.